Captopril — Discount Pricing

Other medications in Heart & Cardiovascular

• Carvedilol
• Chlorthalidone
• Cholestyramine
• Colesevelam
• Colestipol
• Colestipol (Lipid)
• Dapagliflozin (HF)
• Digoxin

About Captopril

Captopril is a vital medication prescribed for various cardiovascular conditions, helping millions manage their health effectively. While essential, the cost of prescription drugs can be a concern. TheDrugClub is dedicated to making crucial medications like Captopril accessible and affordable, ensuring our members receive the care they need without financial burden.

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Captopril is approved for (FDA label)

Hypertension Captopril tablets are indicated for the treatment of hypertension. In using captopril tablets, consideration should be given to the risk of neutropenia/agranulocytosis (see WARNINGS ). Captopril tablets may be used as initial therapy for patients with normal renal function, in whom the risk is relatively low. In patients with impaired renal function, particularly those with collagen vascular disease, captopril should be reserved for hypertensives who have either developed unacceptable side effects on other drugs, or have failed to respond satisfactorily to drug combinations. Captopril tablets are effective alone and in combination with other antihypertensive agents, especially thiazide- type diuretics. The blood pressure lowering effects of captopril and thiazides are approximately additive.

Source: Read the full FDA label on DailyMed. Label effective date: September 14, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Boxed warning for Captopril (FDA label)

WARNING: FETAL TOXICITY When pregnancy is detected, discontinue captopril tablets as soon as possible. Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus. See WARNINGS: Fetal Toxicity

Source: FDA prescribing information (DailyMed). Set ID: 1395ba5b-2fc9-41ff-9c43-e0740d781dee. SPL document ID: 25806eb6-45bd-4684-887c-5ae1705ec201. Label effective date: September 14, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Captopril (FDA label)

Reported incidences are based on clinical trials involving approximately 7000 patients. Renal About one of 100 patients developed proteinuria (see WARNINGS ). Each of the following has been reported in approximately 1 to 2 of 1000 patients and are of uncertain relationship to drug use: renal insufficiency, renal failure, nephrotic syndrome, polyuria, oliguria, and urinary frequency. Hematologic Neutropenia/agranulocytosis has occurred (see WARNINGS ). Cases of anemia, thrombocytopenia, and pancytopenia have been reported. Dermatologic Rash, often with pruritus, and sometimes with fever, arthralgia, and eosinophilia, occurred in about 4 to 7 (depending on renal status and dose) of 100 patients, usually during the first four weeks of therapy. It is usually maculopapular, and rarely urticarial.

Source: FDA prescribing information (DailyMed). Set ID: 1395ba5b-2fc9-41ff-9c43-e0740d781dee. SPL document ID: 25806eb6-45bd-4684-887c-5ae1705ec201. Label effective date: September 14, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Captopril (FDA label)

Captopril tablets are contraindicated in patients who are hypersensitive to this product or any other angiotensin- converting enzyme inhibitor (e.g., a patient who has experienced angioedema during therapy with any other ACE inhibitor). Do not co-administer aliskiren with captopril tablets in patients with diabetes (see PRECAUTIONS : Drug Interactions ). Captopril tablets are contraindicated in combination with a neprilysin inhibitor (e.g., sacubitril). Do not administer captopril tablets within 36 hours of switching to or from sacubitril/valsartan, a neprilysin inhibitor (see PRECAUTIONS : Drug Interactions ).

Source: FDA prescribing information (DailyMed). Set ID: 1395ba5b-2fc9-41ff-9c43-e0740d781dee. SPL document ID: 25806eb6-45bd-4684-887c-5ae1705ec201. Label effective date: September 14, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Captopril (FDA label)

Dual Blockade of the Renin-Angiotensin System (RAS) Dual blockade of the RAS with angiotensin receptor blockers, ACE inhibitors, or aliskiren is associated with increased risks of hypotension, hyperkalemia, and changes in renal function (including acute renal failure) compared to monotherapy. Most patients receiving the combination of two RAS inhibitors do not obtain any additional benefit compared to monotherapy. In general, avoid combined use of RAS inhibitors. Closely monitor blood pressure, renal function and electrolytes in patients on captopril tablets and other agents that block the RAS. Do not coadminister aliskiren with captopril tablets in patients with diabetes. Avoid use of aliskiren with captopril tablets in patients with renal impairment (GFR < 60 ml/min).

Source: FDA prescribing information (DailyMed). Set ID: 1395ba5b-2fc9-41ff-9c43-e0740d781dee. SPL document ID: 25806eb6-45bd-4684-887c-5ae1705ec201. Label effective date: September 14, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.